These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 22036081

  • 1. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.
    Padowski JM, Pollack GM.
    Brain Res; 2011 Dec 02; 1426():1-17. PubMed ID: 22036081
    [Abstract] [Full Text] [Related]

  • 2. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J, Pollack GM.
    J Pharmacol Exp Ther; 2003 Aug 02; 306(2):556-62. PubMed ID: 12721332
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.
    Drug Metab Lett; 2012 Jun 01; 6(2):134-44. PubMed ID: 23061481
    [Abstract] [Full Text] [Related]

  • 5. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
    Zhao R, Pollack GM.
    Biochem Pharmacol; 2009 Oct 15; 78(8):1052-9. PubMed ID: 19523457
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
    Smith BJ, Doran AC, McLean S, Tingley FD, O'Neill BT, Kajiji SM.
    J Pharmacol Exp Ther; 2001 Sep 15; 298(3):1252-9. PubMed ID: 11504828
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
    Kalvass JC, Olson ER, Pollack GM.
    Drug Metab Dispos; 2007 Mar 15; 35(3):455-9. PubMed ID: 17178769
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux.
    Suzuki T, Miyata M, Zaima C, Furuishi T, Fukami T, Kugawa F, Tomono K.
    J Pharm Sci; 2010 Jan 15; 99(1):413-21. PubMed ID: 19530072
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.
    Murata M, Tamai I, Kato H, Nagata O, Tsuji A.
    J Pharmacol Exp Ther; 1999 Jul 15; 290(1):51-7. PubMed ID: 10381759
    [Abstract] [Full Text] [Related]

  • 20. An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood-brain barrier.
    Yang ZH, Sun X, Mei C, Sun XB, Liu XD, Chang Q.
    J Asian Nat Prod Res; 2011 Dec 15; 13(12):1087-97. PubMed ID: 22115032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.